HCA
HALO icon

Heck Capital Advisors’s Halozyme HALO Stock Holding History

Heck Capital Advisors’s Portfolio HALO Stock Details HALO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-605
Closed -$28.9K – 476
2024
Q4 		$28.9K Buy
+605
New +$31K ﹤0.01% 435

Other funds holding HALO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
SCM
Snyder Capital Management San Francisco, California $5.79B AUM 33.56% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Heck Capital Advisors's HALO Position: Q1 2025 in Review

Heck Capital Advisors sold out of Halozyme (HALO) in Q1 2025, closing a stake of 605 shares — an estimated $28.9K sold.

Heck Capital Advisors first reported a position in HALO in Q4 2024 and held it in 1 quarter. The position peaked at $28.9K in Q4 2024. 550 funds tracked by Wall St. Rank hold HALO as of Q1 2025.

  • Heck Capital Advisors reported no remaining Halozyme position as of Q1 2025 after selling out during the quarter.
  • Heck Capital Advisors sold 605 Halozyme shares in Q1 2025, an estimated $28.9K.
  • Heck Capital Advisors first reported a position in Halozyme in Q4 2024 and held it in 1 quarter.
  • Heck Capital Advisors's Halozyme position peaked at $28.9K in Q4 2024.
  • 550 funds tracked by Wall St. Rank held Halozyme as of Q1 2025.

Based on Heck Capital Advisors's 13F filing for Q1 2025, filed 13 May 2025.